Interchangeable Biosimilars Have Arrived In The U.S. – Life Sciences, Biotechnology & Nanotechnology
02 May 2024 Kramer Levin Naftalis & Frankel LLP To print this article, all you need is to be registered or login on Mondaq.com. On July 28, 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar product, Semglee (insulin glargine-yfgn), as a diabetes treatment. Semglee is both biosimilar…